Promising Results: N-acetylglucosamine Restores Neurological Function in Multiple Sclerosis Patients
A clinical trial conducted by researchers at the University of California, Irvine (UCI) suggests that N-acetylglucosamine, a simple sugar, may restore neurological function in multiple sclerosis (MS) patients. The trial found that N-acetylglucosamine reduced inflammation and neurodegeneration markers in MS patients, and improved neurological function in 30% of the participants. The study highlights the potential of N-acetylglucosamine as a treatment for chronic-active neuroinflammation and myelin repair in MS, but further blinded studies are needed to validate its effectiveness.